Skip to main content
. 2019 Apr 9;42(5):553–560. doi: 10.1002/clc.23176

Figure 1.

Figure 1

A, Antithrombotic treatment at baseline by CHA2DS2‐VASc score for all patients in Argentina, Brazil, Chile and Mexico. B, Antithrombotic treatment at baseline by HAS‐BLED score for all patients in Argentina, Brazil, Chile and Mexico. AP, antiplatelet; DTIs, direct thrombin inhibitors; FXas, factor Xa inhibitors; VKAs, vitamin K antagonists